✦ LIBER ✦

Lymphoma in inflammatory bowel disease

✍ Scribed by Adrian J. Greenstein; Gerard E. Mullin; James A. Strauchen; Tomas Heimann; Henry D. Janowitz; Arthur H. Aufses Jr; David B. Sachar

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 481 KB
Volume: 69
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.2820690510

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lymphoma risk in inflammatory bowel dise

Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?

✍ Jennifer L. Jones; Edward V. Loftus Jr. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

With the increasingly widespread use of immunosuppressive and biologic agents for the treatment of Crohn's disease and ulcerative colitis come concerns about potential long-term consequences of such therapies. Disentangling the potential confounding effects of the underlying disease, its extent, sev

Risk of malignant lymphoma in patients w

Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study

✍ A.C.W. Vos; N. Bakkal; R.C. Minnee; M.K. Casparie; D.J. de Jong; G. Dijkstra; P. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 2 views

Background: Immune suppressant medications such as thiopurines and anti-tumor necrosis factor agents are important for maintaining disease control in most patients with inflammatory bowel diseases (IBDs); however, their use has been associated with the development of malignant lymphoma. The purpose

Primary intestinal lymphoma in patients

Primary intestinal lymphoma in patients with inflammatory bowel disease: A descriptive series from the prebiologic therapy era

✍ Stefan D. Holubar; Eric J. Dozois; Edward V. Loftus Jr; Swee H. Teh; Luis A. Ben 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB

## Background: Primary intestinal lymphoma in the setting of inflammatory bowel disease (ibd) is uncommon and may be associated with immune suppressive therapy. we report clinical features and outcomes in patients with both conditions prior to use of biologic therapy. ## Methods: All patients wit

MicroRNAs in inflammatory bowel disease

✍ Joel R. Pekow; John H. Kwon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene and protein expression. miRNAs are critical to a normal immune response and have altered expression in multiple immune-mediated disorders. This emerging role of miRNAs in the pathogenesis of multiple disease states has led to investigat

Antimicrobial cover in inflammatory bowe

Antimicrobial cover in inflammatory bowel disease

✍ R. V. Fiddian; M. R. B. Keighley 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

Pyoderma gangrenosum in inflammatory bow

Pyoderma gangrenosum in inflammatory bowel disease

✍ M. D. Levitt; J. K. Ritchie; J. E. Lennard-Jones; Mr. R. K. S. Phillips 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 2 views